An NCI-designated Comprehensive Cancer Center
By City of Hope | October 7, 2018
City of Hope researchers are actively recruiting for patients 60 years and older for a phase 2 trial studying the side effects of and how well neratinib works in treating older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has spread from where it started to other places in the body.  Yuan Yuan, M.D., Ph.D., associate clinical professor, Department of Medical Oncology & Therapeutics Research, is the principal investigator for this study.
Although there has been a growth in the number of targeted agents approved for the treatment of breast cancer, there are limited data regarding the efficacy, toxicity and management of side effects in older adults.
The tolerability and toxicity profile of neratinib is being evaluated in an open-label, single-arm, phase 2 study in patients 60 and older with HER2+ overexpressed or mutated metastatic breast cancer (NCT02673398). The trial design incorporates geriatric oncology considerations, with some unique factors considered, including:
  • Pretreatment and on-treatment geriatric assessment
  • Additional nurse toxicity visits
  • Aggressive management of diarrhea using an algorithm
  • Measuring the pharmacokinetics of neratinib
  • The inclusion of biomarkers of aging
  • Evaluating patient adherence
  • Measuring quality of life
To see if you’re eligible to join this trial, view the participant criteria here. For enrollment information, please contact Yuan by phone at 800-826-4673, or by email at [email protected].

Subscribe to Physician News for the latest developments in diabetes and cancer prevention, treatment, research, clinical trials and upcoming continuing medical education (CME) programs.
We will always respect your privacy and you may unsubscribe at any time. We will never sell or exchange your information with others. View our complete Privacy Policy .

*Required Fields